Management of Treatment-Experienced Patients With HIV

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/13/21 (What's New)

Summary

  • HIV-1 RNA persistently above the limits of assay detection up to 1000 copies/mL is distinct from clinically irrelevant “blips”
  • Initial focus should be to assess adherence and potential for drug–drug or drug–food interactions
  • Considerable data and DHHS guidance support modifying the regimen of treatment-experienced patients with HIV-1 RNA persistently > 200 copies/mL to one of the following switch options[Aboud 2019]

    Action required

    Keywords: Management of Treatment-Experienced Patients, Resistance Testing

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.